GlassScriptPhysician profile
Tony Trpkovski
NPI 1679678379
$1,355.57
in general payments reported to CMS, 2019-2025
12 companies · $21.39 in 2025
The $21.39 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $252 · 2021: $380 · 2022: $29.57 · 2023: $225 · 2024: $69.14 · 2025: $21.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.22 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $224.52 | 2019-2023 | Mounjaro |
| Gilead Sciences, INC. | $138.41 | 2019-2023 | |
| Pfizer INC. | $105.36 | 2023-2025 | |
| Genentech USA, INC. | $66.59 | 2019-2020 | |
| Amarin Pharma, INC. | $60.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $47.98 | 2019 | |
| Galt Pharmaceuticals, LLC | $42.96 | 2023 | Orphengesic Forte |
| Takeda Pharmaceuticals U.S.A., INC. | $30.99 | 2019 | |
| Irhythm Technologies, INC. | $24.75 | 2019 | |
| Idorsia Pharmaceuticals US INC | $22.61 | 2023 | Quviviq |
| Abbvie INC. | $17.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Trpkovski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.